Cargando…

Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis

Biosimilars are increasingly available for the treatment of many serious disorders, however some concerns persist about switching a patient to a biosimilar whose condition is stable while on the reference biologic. Randomized controlled studies and extension studies with a switch treatment period (S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herndon, Thomas M., Ausin, Cristina, Brahme, Nina N., Schrieber, Sarah J., Luo, Michelle, Andrada, Frances C., Kim, Carol, Sun, Wanjie, Zhou, Lingjie, Grosser, Stella, Yim, Sarah, Ricci, M. Stacey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547155/ https://www.ncbi.nlm.nih.gov/pubmed/37788264 http://dx.doi.org/10.1371/journal.pone.0292231

Ejemplares similares

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
por: Cohen, Hillel P., et al.
Publicado: (2022)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
por: Cohen, Hillel P., et al.
Publicado: (2018)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Pires, Antonio, et al.
Publicado: (2018)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
por: Panaccione, Remo
Publicado: (2021)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics
por: Limdi, Jimmy K, et al.
Publicado: (2021)

Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018)

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017)

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
por: Petit, Juliette, et al.
Publicado: (2021)

A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn’s Disease
por: Hughes, Avery, et al.
Publicado: (2020)

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
por: Abdalla, Abuelmagd, et al.
Publicado: (2017)

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis
por: Ascef, Bruna O., et al.
Publicado: (2021)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

A ‘Global Reference’ Comparator for Biosimilar Development
por: Webster, Christopher J., et al.
Publicado: (2017)

The Law and Ethics of Switching from Biologic to Biosimilar in Canada
por: Murdoch, Blake, et al.
Publicado: (2020)

Safety of switching between rituximab biosimilars in onco-hematology
por: Urru, Silvana A. M., et al.
Publicado: (2021)

Switching Among Biosimilars: A Review of Clinical Evidence
por: Allocati, Eleonora, et al.
Publicado: (2022)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
por: Pierik, Marieke J, et al.
Publicado: (2021)

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Cohen, Hillel P., et al.
Publicado: (2018)

Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab
por: Łosińska, Katarzyna, et al.
Publicado: (2023)

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial
por: Cohen, Stanley B., et al.
Publicado: (2020)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Switching Between Epoetins: A Practice in Support of Biosimilar Use
por: D’Amore, Carmen, et al.
Publicado: (2016)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
por: Kristensen, Lars Erik, et al.
Publicado: (2018)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
por: Fleischmann, Roy M., et al.
Publicado: (2021)

Glycosylation Pattern and in vitro Bioactivity of Reference Follitropin alfa and Biosimilars
por: Riccetti, Laura, et al.
Publicado: (2019)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
por: Fleischmann, Roy M, et al.
Publicado: (2021)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars
por: Mazzoni, Davide, et al.
Publicado: (2021)

Advancing Biosimilar Development Using Pharmacodynamic Biomarkers in Clinical Pharmacology Studies
por: Li, Junyi, et al.
Publicado: (2019)

Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study
por: Kaltsonoudis, Evripidis, et al.
Publicado: (2019)

Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis
por: de Oliveira Ascef, Bruna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jphnv3vo6noq8uck4p1apbes0q